Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect

Area of Science:

• Nephrology
• Hematology
• Biochemistry

Background:

• Renal failure and uremia are linked to qualitative platelet abnormalities and bleeding tendencies.
• Previous studies indicated abnormal platelet aggregation and reduced malondialdehyde production in uremic patients.

Purpose of the Study:

• Compare platelet prostaglandin (PG) and thromboxane (TX) production in uremic patients versus healthy controls.
• Evaluate platelet PG- and TX-forming enzyme activity and concentration.
• Assess platelet TXA2/PGH2 receptor responsiveness.
• Explore hemostatic consequences of reduced TXA2 production.

Main Methods:

• Measured immunoreactive TXB2 and PGE2 production in whole blood and platelet-rich plasma (PRP).
• Assessed PGH synthase levels via immunoradiometric assay.
• Administered aspirin to healthy volunteers to mimic uremic TXB2 levels.
• Evaluated platelet aggregation responses to ADP, arachidonic acid, U46619, and prostacyclin.

Main Results:

• Uremic patients exhibited significantly reduced platelet TXB2 production (~60%) during whole blood clotting.
• Exogenous thrombin did not normalize TXB2 production in uremic platelets.
• Uremic PRP showed reduced TXB2 production at higher arachidonate concentrations (>2 mM).
• Synthesis of cyclooxygenase products (TXB2, PGE2, PGI2) was slower and reduced in uremia.
• PGH synthase levels were not significantly different between uremic and control platelets.
• Aspirin-induced reduction of TXB2 in healthy volunteers mimicked uremic platelet aggregation and bleeding times.
• Uremic platelets showed normal responsiveness to TXA2 agonist (U46619) and prostacyclin.

Conclusions:

• Uremia is associated with an abnormality in platelet arachidonic acid metabolism, specifically reduced TXA2 production.
• This defect appears to stem from functional cyclooxygenase impairment.
• Diminished TXA2 production likely contributes to the observed platelet dysfunction in uremia.